Galapagos is a fully integrated biotechnology company focused on discovering, developing and commercializing innovative medicines. We are committed to improving patients’ lives worldwide by targeting diseases with high unmet needs. Our capabilities cover multiple drug modalities, including small molecules and cell therapies. Our portfolio comprises discovery through to commercial programs in immunology, oncology, and other indications. Our first medicine for rheumatoid arthritis and ulcerative colitis is approved and available in Europe and Japan.
Ticker:
GLPG
Exchange:
Dual listing on Euronext Amsterdam and Brussels, and on the NASDAQ
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
NA
Company HQ Country:
Belgium
Year Founded:
1999
Main Therapeutic Focus:
Oncology
Lead Product in Development:
Jyseleca (approved in Europe and Japan for rheumatoid arthritis and Ulcerative Collitis and phase 2 for Axial Spondyloarthritis), GLPG3667 in phase 2 for dermatomyositis, CD19 CAR-T in phase 1 for NHL and CLL, BCMA CAR-T for MM
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
